Small Steatotic HCC: A Radiological Variant Associated With Improved Outcome After Ablation.
Journal
Hepatology communications
ISSN: 2471-254X
Titre abrégé: Hepatol Commun
Pays: United States
ID NLM: 101695860
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
17
09
2020
revised:
02
12
2020
accepted:
08
12
2020
entrez:
16
4
2021
pubmed:
17
4
2021
medline:
17
4
2021
Statut:
epublish
Résumé
Percutaneous thermal ablation is a validated treatment option for small hepatocellular carcinoma (HCC). Steatotic HCC can be reliably detected by magnetic resonance imaging. To determine the clinical relevance of this radiological variant, we included 235 patients (cirrhosis in 92.3%, classified Child-Pugh A in 97%) from a prospective database on percutaneous thermal ablation for <3 cm HCC. Among these patients, 52 (22.1%) had at least one steatotic HCC nodule. Nonalcoholic steatohepatitis was more frequent in patients with than without steatotic HCC (
Identifiants
pubmed: 33860126
doi: 10.1002/hep4.1661
pii: 02009842-202104000-00015
pmc: PMC8034567
doi:
Types de publication
Journal Article
Langues
eng
Pagination
689-700Informations de copyright
© 2020 The Authors. Hepatology Communications published by Wiley Periodicals LLC on behalf of the American Association for the Study of Liver Diseases.
Références
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394‐424.
EASL Clinical Practice Guidelines . Management of hepatocellular carcinoma. J Hepatol 2018;69:182‐236.
Nault JC, Sutter O, Nahon P, Ganne‐Carrie N, Seror O. Percutaneous treatment of hepatocellular carcinoma: state of the art and innovations. J Hepatol 2018;68:783‐797.
Livraghi T, Meloni F, Di Stasi M, Rolle E, Solbiati L, Tinelli C, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? Hepatology 2008;47:82‐89.
N'Kontchou G, Mahamoudi A, Aout M, Ganne‐Carrié N, Grando V, Coderc E, et al. Radiofrequency ablation of hepatocellular carcinoma: long‐term results and prognostic factors in 235 Western patients with cirrhosis. Hepatology (Baltimore, MD) 2009;50:1475‐1483.
Liver. EAftSot . EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018;69:182‐236.
Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003;38:200‐207.
Calderaro J, Couchy G, Imbeaud S, Amaddeo G, Letouzé E, Blanc J‐F, et al. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. J Hepatol 2017;67:727‐738.
Calderaro J, Ziol M, Paradis V, Zucman‐Rossi J. Molecular and histological correlations in liver cancer. J Hepatol 2019;71:616‐630.
Ziol M, Poté N, Amaddeo G, Laurent A, Nault J‐C, Oberti F, et al. Macrotrabecular‐massive hepatocellular carcinoma: a distinctive histological subtype with clinical relevance. Hepatology 2018;68:103‐112.
Salomao M, Yu WM, Brown RS, Emond JC, Lefkowitch JH. Steatohepatitic hepatocellular carcinoma (SH‐HCC): a distinctive histological variant of HCC in hepatitis C virus‐related cirrhosis with associated NAFLD/NASH. Am J Surgical Pathol 2010;34:1630‐1636.
Chan AWH, Yu S, Yu Y‐H, Tong JHM, Wang L, Tin EKY, et al. Steatotic hepatocellular carcinoma: a variant associated with metabolic factors and late tumour relapse. Histopathology 2016;69:971‐984.
Salomao M, Remotti H, Vaughan R, Siegel AB, Lefkowitch JH, Moreira RK. The steatohepatitic variant of hepatocellular carcinoma and its association with underlying steatohepatitis. Hum Pathol 2012;43:737‐746.
Shibahara J, Ando S, Sakamoto Y, Kokudo N, Fukayama M. Hepatocellular carcinoma with steatohepatitic features: a clinicopathological study of Japanese patients. Histopathology 2014;64:951‐962.
Lee JS, Yoo JE, Kim H, Rhee H, Koh MJ, Nahm JH, et al. Tumor stroma with senescence‐associated secretory phenotype in steatohepatitic hepatocellular carcinoma. PLoS One 2017;12:e0171922.
Guiu B, Petit JM, Loffroy R, Ben Salem D, Aho S, Masson D, et al. Quantification of liver fat content: comparison of triple‐echo chemical shift gradient‐echo imaging and in vivo proton MR spectroscopy. Radiology 2009;250:95‐102.
Min JH, Kim YK, Lim S, Jeong WK, Choi D, Lee WJ. Prediction of microvascular invasion of hepatocellular carcinomas with gadoxetic acid‐enhanced MR imaging: impact of intra‐tumoral fat detected on chemical‐shift images. Eur J Radiol 2015;84:1036‐1043.
Hermida M, Cassinotto C, Piron L, Aho‐Glele S, Guillot C, Schembri V, et al. Multimodal percutaneous thermal ablation of small hepatocellular carcinoma: predictive factors of recurrence and survival in Western patients. Cancers (Basel) 2020;12:313.
Guiu B, Petit J‐M, Loffroy R, Ben Salem D, Aho S, Masson D, et al. Quantification of liver fat content: comparison of triple‐echo chemical shift gradient‐echo imaging and in vivo proton MR spectroscopy. Radiology 2009;250:95‐102.
Wang C, He W, Yuan Y, Zhang Y, Li K, Zou R, et al. Comparison of the prognostic value of inflammation‐based scores in early recurrent hepatocellular carcinoma after hepatectomy. Liver Int 2020;40:229‐239.
Cardella JF, Kundu S, Miller DL, Millward SF, Sacks D, Society of Interventional Radiology . Society of Interventional Radiology clinical practice guidelines. J Vasc Interv Radiol 2009;20:S189‐S191.
Ahmed M, Solbiati L, Brace CL, Breen DJ, Callstrom MR, Charboneau JW, et al. Image‐guided tumor ablation: standardization of terminology and reporting criteria—a 10‐year update. J Vasc Interv Radiol 2014;25:1691‐1705.e1694.
Kutami R, Nakashima Y, Nakashima O, Shiota K, Kojiro M. Pathomorphologic study on the mechanism of fatty change in small hepatocellular carcinoma of humans. J Hepatol 2000;33:282‐289.
Jain D, Nayak NC, Kumaran V, Saigal S. Steatohepatitic hepatocellular carcinoma, a morphologic indicator of associated metabolic risk factors: a study from India. Arch Pathol Lab Med 2013;137:961‐966.
Alexander J, Torbenson M, Wu TT, Yeh MM. Non‐alcoholic fatty liver disease contributes to hepatocarcinogenesis in non‐cirrhotic liver: a clinical and pathological study. J Gastroenterol Hepatol 2013;28:848‐854.
Taniai M, Hashimoto E, Tobari M, Kodama K, Tokushige K, Yamamoto M, et al. Clinicopathological investigation of steatohepatitic hepatocellular carcinoma: a multicenter study using immunohistochemical analysis of adenoma‐related markers. Hepatol Res 2018;48:947‐955.
Olofson AM, Gonzalo DH, Chang M, Liu X. Steatohepatitic variant of hepatocellular carcinoma: a focused review. Gastroenterology Res 2018;11:391‐396.
Yeh MM, Liu Y, Torbenson M. Steatohepatitic variant of hepatocellular carcinoma in the absence of metabolic syndrome or background steatosis: a clinical, pathological, and genetic study. Hum Pathol 2015;46:1769‐1775.
Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer‐related inflammation and treatment effectiveness. Lancet Oncol 2014;15:e493‐e503.
Chua DW, Koh YX, Liew YX, Chan C‐Y, Lee S‐Y, Cheow P‐C, et al. Pre‐operative predictors of early recurrence/mortality including the role of inflammatory indices in patients undergoing partial hepatectomy for spontaneously ruptured hepatocellular carcinoma. J Surg Oncol 2018;118:1227‐1236.
Hu B, Yang X‐R, Xu Y, Sun Y‐F, Sun C, Guo W, et al. Systemic immune‐inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res 2014;20:6212‐6222.
Wang B‐L, Tian LU, Gao X‐H, Ma X‐L, Wu J, Zhang C‐Y, et al. Dynamic change of the systemic immune inflammation index predicts the prognosis of patients with hepatocellular carcinoma after curative resection. Clin Chem Lab Med 2016;54:1963‐1969.
Doyle A, Gorgen A, Muaddi H, Aravinthan AD, Issachar A, Mironov O, et al. Outcomes of radiofrequency ablation as first‐line therapy for hepatocellular carcinoma less than 3 cm in potentially transplantable patients. J Hepatol 2019;70:866‐873.
Hocquelet A, Balageas P, Laurent C, Blanc J‐F, Frulio N, Salut C, et al. Radiofrequency ablation versus surgical resection for hepatocellular carcinoma within the Milan criteria: a study of 281 Western patients. Int J Hyperthermia 2015;31:749‐757.
Kim Y‐S, Lim HK, Rhim H, Lee MW, Choi D, Lee WJ, et al. Ten‐year outcomes of percutaneous radiofrequency ablation as first‐line therapy of early hepatocellular carcinoma: analysis of prognostic factors. J Hepatol 2013;58:89‐97.
Lee DH, Lee JM, Lee JY, Kim SH, Yoon JH, Kim YJ, et al. Radiofrequency ablation of hepatocellular carcinoma as first‐line treatment: long‐term results and prognostic factors in 162 patients with cirrhosis. Radiology 2014;270:900‐909.
Pompili M, Saviano A, de Matthaeis N, Cucchetti A, Ardito F, Federico B, et al. Long‐term effectiveness of resection and radiofrequency ablation for single hepatocellular carcinoma </=3 cm. Results of a multicenter Italian survey. J Hepatol 2013;59:89‐97.
Hasegawa K, Kokudo N, Makuuchi M, Izumi N, Ichida T, Kudo M, et al. Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey. J Hepatol 2013;58:724‐729.
Cucchetti A, Piscaglia F, Cescon M, Colecchia A, Ercolani G, Bolondi L, et al. Cost‐effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma. J Hepatol 2013;59:300‐307.
Nault J‐C, Martin Y, Caruso S, Hirsch TZ, Bayard Q, Calderaro J, et al. Clinical impact of genomic diversity from early to advanced hepatocellular carcinoma. Hepatology 2020;71:164‐182.